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Objective: Abdominal obesity and its associated metabolic consequences are major determinants for the development of
vascular disease. Fat tissue close to arteries may also directly affect atherogenesis. The study examined whether
intra-abdominal fat accumulation is an independent determinant of infrarenal aortic diameter in patients with clinically
evident arterial disease. The relationship between metabolic syndrome and infrarenal aortic diameter was also assessed in
this patient group.
Methods: Cross-sectional study was done of 2726 patients with clinically evident arterial disease enrolled in the Second
Manifestations of ARTerial Disease (SMART) study. Intra-abdominal fat was measured with ultrasonography and by
measuring waist circumference. Metabolic syndrome was defined according to the Adult Treatment Panel III. The
maximal anteroposterior diameter of the infrarenal aorta was measured using ultrasonography. The relation between
intra-abdominal fat, metabolic syndrome, and infrarenal aortic diameter was determined with linear regression analyses
and adjusted for age, sex, height, and smoking.
Results: Infrarenal aortic diameters (mm) increased across quartiles of intra-abdominal fat derived by ultrasonography
(quartile 4, 19  7 mm vs quartile 1, 17  5 mm; adjusted , 1.34; 95% confidence interval [CI], 0.73-1.94) and across
quartiles of waist circumference (quartile 4, 19 7 mm vs quartile 1, 17 5 mm; adjusted , 1.43; 95% CI, 0.82-2.04).
Patients with metabolic syndrome had slightly larger infrarenal aortic diameters (18  7 mm vs 17  6 mm; adjusted ,
0.70; 95% CI, 0.27-1.13) compared with those without metabolic syndrome.
Conclusions: Intra-abdominal fat accumulation and metabolic syndrome are associated with larger infrarenal aortic
diameters in patients with clinically evident arterial disease. These data may indicate a role for intra-abdominal fat in the
development of larger aortic diameters. ( J Vasc Surg 2008;48:114-20.)Abdominal obesity is associated with an increased risk
of atherosclerotic vascular disease.1 Intra-abdominal fat
accumulation causes an altered adipocyte function, leading
to high systemic plasma levels of tumor necrosis factor-
(TNF-), interleukine-6 (IL-6), and free fatty acids, as well
as low plasma concentrations of adiponectin, all of which
are involved in accelerating atherosclerosis2 and contribut-
ing to the development of insulin resistance.3 Insulin resis-
tance is considered to be an essential feature in the devel-
opment of vascular risk factors such as elevated blood
pressure, dyslipidemia, and hyperglycemia.4 The clustering
of all these metabolic abnormalities, often referred to as
metabolic syndrome,5 is most often the result of obesity-
induced insulin resistance and is associated with a high
cardiovascular risk.6
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114Patients with an enlarged diameter of the abdominal
aortic artery are at high risk for cardiovascular morbidity
and mortality.7,8 In addition to proteolytic degradation
and remodeling of the elastic media,9 atherosclerosis is
recognized as an important feature in the process of aortic
dilatation.10 Indeed, vascular risk factors such as smok-
ing,11-13 elevated blood pressure,13-15 body weight,14-16
and dyslipidemia11-13,15 are associated with an enlarged
diameter of the abdominal aorta in the general population.
Inflammatory cytokines appear to be involved as well16-19
by mediating connective tissue destruction of the aortic
wall.20
Intra-abdominal fat accumulation and its associated
metabolic abnormalities may contribute to the dilatation of
the abdominal aortic artery by accelerating aortic wall de-
generation. Because obesity-related insulin resistance can
induce elevated blood pressure by activation of the sympa-
thetic nerve system, increased renal sodium retention, and
endothelial dysfunction,21 this could be one of the under-
lyingmechanisms.Moreover, obesity-induced insulin resis-
tance and high plasma levels of inflammatory cytokines
might aggravate inflammation in the periaortic fat, which is
close to the aortic adventitia and locally secretes inflamma-
tory cytokines.22
Although increased intra-abdominal fat and metabolic
syndrome are highly prevalent in patients with clinically
evident arterial disease,23 whether they are related to ab-
dominal aortic diameter in these high-risk patients is not
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 1 Gorter et al 115known. The objective of the current etiologic study was to
establish whether intra-abdominal fat accumulation is an
independent determinant of infrarenal aortic diameter in
patients with clinically evident arterial disease. In addition,
the relationship between metabolic syndrome and infrare-
nal aortic diameter was assessed in these patients.
METHODS
Study settings, participants, and design. We used
data from patients enrolled in the SecondManifestations of
ARTerial disease (SMART) study. The SMART study is an
ongoing prospective single-center cohort study. Patients
with clinically evident arterial disease or cardiovascular risk
factors are included.24 Started in September 1996, patients
aged 18 to 80 were referred to the University Medical
Center (UMC) Utrecht with a recent diagnosis of clinically
evident arterial disease or a cardiovascular risk factor. Pa-
tients were excluded if they had a terminal malignant
disease, were not independent in daily activities (Rankin
scale3), or were not sufficiently fluent in Dutch. Patients
entered the SMART study if the treating specialist sup-
ported the patient’s participation and if the patient con-
sented. The Medical Ethics Committee approved the
study, and all participants gave their written informed con-
sent.
The rationale and design of the SMART study and a
detailed description of the criteria used to define the differ-
ent clinically evident arterial diseases was published previ-
ously.24 The aims of the SMART study are to determine (1)
the risk factors for progression of atherosclerosis in patients
with evident arterial disease, (2) the prevalence of addi-
tional vascular disease, and (3) the incidence of future
cardiovascular events.
For the current study, analyses were based on the inclu-
sion period fromMay 2000 to March 2007 and were limited
to 3020 patients with clinically evident arterial disease, includ-
ing coronary heart disease, cerebrovascular disease, peripheral
arterial disease, or abdominal aortic aneurysm. Excluded were
64 patients with previous surgery for abdominal aortic aneu-
rysm, 195 patients because of incomplete data for waist cir-
cumference and intra-abdominal fat, and 35 patients owing to
poor visualization of the aorta. Finally, 2726 patients were
included for the analyses.
Data acquisition. All patients underwent a noninva-
sive standardized diagnostic protocol on a single day at the
UMCUtrecht. Medical history, use of current medication,
and current and past smoking behavior were derived from a
standardized health questionnaire described elsewhere.24 A
physical examination included weight, height, waist cir-
cumference, and diastolic and systolic blood pressure.
Height and weight were measured while participants wore
indoor clothes and no shoes. Blood pressure was measured
twice in a sitting position at the right and left upper arm
with a nonrandom sphygmomanometer, and the mean
value was taken as the blood pressure. Blood samples were
collected after an overnight fast. Levels of total cholesterol,
triglycerides, high-density lipoprotein (HDL) cholesterol,
glucose, and creatinine were measured. Low-density li-poprotein (LDL) cholesterol was calculated by use of the
Friedewald formula if the triglyceride plasma level was4.5
mmol/L. The left and right ankle-brachial pressure indexes
(ABPI) at rest were determined.24
Definitions. Metabolic syndrome was defined accord-
ing to the Adult Treatment Panel III criteria.5 Metabolic
syndrome requires the presence of at least three of the
following metabolic abnormalities:
● abdominal obesity, defined as waist circumference
102 cm in men and 88 cm in women;
● high blood pressure, defined as130 mm Hg systolic
or 85 mm Hg diastolic;
● hypertriglyceridemia, defined as serum triglycerides
1.70 mmol/L (150 mg/dL);
● low serum HDL cholesterol level, defined as 1.04
mmol/L (40mg/dL) inmen and1.29mmol/L (50
mg/dL) in women;
● high fasting serum glucose level, defined as 5.6
mmol/L [100 mg/dL].
Patients taking glucose-lowering agents or antihyperten-
sive medication were regarded as having high fasting glu-
cose or high blood pressure, respectively.
Presence of documented diabetes mellitus was ascer-
tained by medical history (use of glucose-lowering medica-
tions). Ever smoking was defined as current or past smok-
ing; that is, patients who currently smoke, patients who
recently stopped smoking, and patients who have smoked
in the past. A reduced ABPI was defined as a resting ABPI
0.9.24
Assessment of intra-abdominal fat. Intra-abdominal
fat was estimated anthropometrically and by ultrasound
imaging. Waist circumference was measured halfway be-
tween the lower rib and the iliac crest and was taken in the
standing position at the end of a normal expiration. Ab-
dominal B-mode ultrasound imaging to measure intra-
abdominal fat was performed by well-trained registered
vascular technologists in a certified vascular laboratory.
Ultrasonographic measurements were made in supine po-
sition using an ATL HDI 3000 (Advanced Technology
Laboratories, Philips Medical Systems, Eindhoven, Neth-
erlands) with a C 4-2 transducer. No bowel preparation was
performed before the ultrasound measurement.
Intra-abdominal fat was ultrasonographically measured
as the distance between the peritoneum and the lumbar
spine or psoas muscles using electronic calipers. A strict
protocol, including the position of and pressure on the
transducer, was used. The transducer was placed on a
straight line drawn between the left and right midpoints of
the lower rib and the iliac crest. Measurements were per-
formed at the end of a quiet inspiration, applying minimal
pressure without displacement or compression of the ab-
dominal cavity. The distance was measured three times at
three different positions.25
Previously, the ultrasound protocol for measuring
intra-abdominal fat was compared with computed tomog-
raphy (CT) at our center.25 Ultrasonographic measure-
ments were strongly associated with CT measurements of
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inter-observer coefficient of variation of 5.4% was found for
ultrasound measurements of intra-abdominal fat, indicat-
ing good reproducibility.25
Assessment of infrarenal aortic diameter. B-mode
ultrasound scanning was done to measure the maximal
anteroposterior diameter of the infrarenal aorta using the
same ATL HDI 3000 as for intra-abdominal fat. The
measurements were performed in transverse sections, tak-
ing special care to perform the diameter measurements
perpendicular to the longitudinal axis of the vessel. The
echo-free lumen of the vessel was measured between the
inner edge of the anterior wall and the inner edge of
the posterior wall.24 Ultrasonography is a reliable method
to assess the infrarenal aortic diameter.26,27
Statistical analysis. The association between intra-
abdominal fat and infrarenal aortic diameter was quantified
using linear regression analysis. The residuals were normally
distributed. Intra-abdominal fat was categorized into quar-
tiles, and the lowest quartile was considered as the refer-
ence. Quartiles for intra-abdominal fat (measured with
ultrasonography and by measuring waist circumference)
were made separately for men and women; for all other
variables, quartiles were based on the distribution of the
total population. Results are expressed as  coefficients with
95% confidence intervals (CI).
Three models were used to estimate the relation be-
tween intra-abdominal fat as an independent and infrarenal
aortic diameter as a dependent variable. In the first model,
adjustments were made for age and sex. In the second
model, additional adjustments were performed for other
potentially confounding variables, namely height and ever
smoking. In the third model, additional adjustment was
performed for the intermediate variables of triglycerides,
HDL cholesterol, fasting glucose, and systolic blood pres-
sure to investigate whether they explained the association
between intra-abdominal fat and infrarenal aortic diameter.
The covariates were included as continuous variables, ex-
cept sex and ever smoking were included as categoric
variables.
Potential effect modification of a reduced ABPI, pres-
ence of diabetes,28 and presence of coronary artery disease
on the relationship between intra-abdominal fat and infra-
renal aortic diameter was investigated by entering the cross-
products of a reduced ABPI, diabetes, or coronary artery
disease with intra-abdominal fat (continuously) in the re-
gression models. In assessing the potential modifying effect
of a reduced ABPI, 321 diabetic patients were excluded
because ABPI assessment may be inadequate in these pa-
tients owing to media arterial calcification.29 Interaction
was considered present when the interaction term in the
model had a value of P  .05.
Linear regression analysis was also performed with met-
abolic syndrome and the number of components of meta-
bolic syndrome as independent variables, respectively, and
infrarenal aortic diameter as the dependent variable, and
adjusted for age, sex, height and ever smoking. The resid-
uals were normally distributed.To reduce bias and increase statistical efficiency, miss-
ing values in the data for fasting glucose (n  33), total
cholesterol (n  23), triglycerides (n  30), HDL choles-
terol (n  30), creatinine (n  26), diastolic (n  10) and
systolic (n  10) blood pressure, and ABPI (n  17) were
completed by regression imputation.30,31
RESULTS
Baseline characteristics. Table I reports the baseline
characteristics of the study population and according to
quartiles of ultrasonographically measured intra-abdominal
fat. The distribution of characteristics was comparable
across quartiles of waist circumference (data not shown).
Mean age was 59 10 years, and 74% of patients weremen.
Mean intra-abdominal fat was 9.3  2.6 cm, and mean
waist circumference was 95  12 cm. Prevalence of meta-
bolic syndrome was 46% and was more prevalent in the
highest quartile of ultrasonographically measured intra-
abdominal fat than in the lowest quartile (78% vs 19%).
Individual components of metabolic syndrome were gen-
erally more adverse among patients with more intra-
abdominal fat. The prevalence of AAA was 5% in patients
with coronary artery disease, 6% in patients with peripheral
arterial disease, and 2% in patients with cerebrovascular
disease.
Intra-abdominal fat measurements in relation to
infrarenal aortic diameter. Mean infrarenal aortic diam-
eter was 18  6 mm; men had larger infrarenal aortic
diameters than women, at 19  6 mm vs 15  4 mm.
Infrarenal aortic diameter was 19  7 mm in patients
within the highest intra-abdominal fat quartile compared
with 17  5 mm in patients within the lowest quartile.
Infrarenal aortic diameter (mm) increased across quar-
tiles of intra-abdominal fat (quartile 4 vs quartile 1: ,
1.39; 95% CI, 0.78-2.00) and across quartiles of waist
circumference (quartile 4 vs quartile 1: , 1.67; 95% CI,
1.06-2.27) after adjustment for age and sex (Table II).
This indicates that patients within the highest quartile of
intra-abdominal fat or waist circumference had, respec-
tively, 1.39 mm and 1.67 mm larger infrarenal aortic
diameters than those within the lowest quartile. Height
and ever smoking did not materially change the relation-
ship of intra-abdominal fat (quartile 4 vs quartile 1: ,
1.34; 95% CI, 0.73-1.94), and waist circumference
(quartile 4 vs quartile 1: , 1.43; 95% CI, 0.82-2.04)
with infrarenal aortic diameter. Additional adjustment
for the intermediate variables of triglycerides, HDL cho-
lesterol, fasting glucose, and systolic blood pressure did
not markedly change the associations (model III). Also,
adding the presence of diabetes or coronary artery dis-
ease or use of statins or use of angiotensin-converting
enzyme inhibitors or weight or body mass index to
model III did not materially affect the relationship be-
tween intra-abdominal fat and infrarenal aortic diameter.
The magnitude of the positive association between
intra-abdominal fat (ultrasonography) and infrarenal aortic
one d
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ABPI (model II: , 0.46; 95% CI, 0.21-0.71), than in the
1955 patients without a reduced ABPI (model II: , 0.19;
95% CI, 0.09-0.30; P  .02 for interaction). The relation-
ship between intra-abdominal fat by ultrasonography and
infrarenal aortic diameter was not modified by the presence
of diabetes (P  .31 for interaction) or the presence of
Table I. Baseline characteristics in 2726 patients with clin
Quartiles of intra-abdominal fat Quartile 1 Q
Demographicsa (n 704) (
Intra-abdominal fat, cm 6.4 1.2 8
Age, years 57 11
Male sex, n (%) 523 (74) 518
Height, m 1.75 0.09 1.
Weight, kg 74 12
Body mass index, kg/m2 24 3
Ever smoking (current or past), No. (%) 537 (76) 545
Diabetes mellitusb 47 (7) 65
Creatinine clearance (mL/min/1.73m2)c 76 21
LDL cholesterol (mmol/L)d 2.5 (2.0-3.3) 2.7
Lipid-lowering agents, No. (%) 417 (59) 420
Blood pressure-lowering agents, No. (%) 412 (59) 449
Metabolic syndrome
Metabolic syndrome ATP III, No. (%) 135 (19) 243
Fasting glucose, mmol/L 5.5 (5.1-6.0) 5.7
Triglycerides, mmol/L 1.14 (0.90-1.53) 1.34
HDL cholesterol, mmol/L 1.30 (1.08-1.61) 1.23
Waist circumference, cm 86 10
Systolic blood pressure (mmHg) 139 22 1
Diastolic blood pressure (mmHg) 81 11
Clinically evident arterial diseasee
Cerebrovascular disease, No. (%) 228 (32) 213
Coronary artery disease, No. (%) 400 (57) 438
Peripheral arterial disease, No. (%) 121 (17) 111
Abdominal aortic aneurysm, No. (%) 34 (5) 45
ATP, Adult Treatment Panel; HDL, high-density lipoprotein; LDL, low-de
aAll data in No. (%), mean  SD, or median (interquartile range).
bPatients taking glucose-lowering agents.
cAccording to Cockroft-Gault.
dCalculated by use of the Friedewald formula.
eEver or current diagnosis. A single person can be classified into more than
Table II. Intra-abdominal fat in relation to infrarenal aort
arterial disease
Model a
Quartile 1 Qu
 (95% CI)b  (
Intra-abdominal fat (cm)
I 0 0.49 (
II 0 0.50 (
III 0 0.46 (
Waist circumference (cm)
I 0 0.42 (
II 0 0.32 (
III 0 0.25 (
aModel I: age and sex adjusted. Model II: model I, additionally adjuste
triglycerides, high-density lipoprotein cholesterol, fasting glucose, and systo
bAll data:  regression coefficients with 95% confidence interval (CI).  Indi
the lowest intra-abdominal fat or waist circumference; for example, patients
aortic diameters than those within the lowest quartile (model II).coronary artery disease (P  .78 for interaction).Metabolic syndrome in relation to infrarenal aortic
diameter. Patients with metabolic syndrome had slightly
larger infrarenal aortic diameters compared with those without
metabolic syndrome, at 18 7 vs 17 6 mm (, 0.70; 95%
CI, 0.27-1.13, adjusted for age, sex, height, and ever smoking;
Table III). Patients with five components of metabolic syn-
drome had larger infrarenal aortic diameters than those with
evident arterial disease
ile 2 Quartile 3 Quartile 4 All patients
01) (n 650) (n 671) (n 2726)
0.9 9.9 0.9 12.7 1.8 9.3 2.6
11 60 10 60 10 59 10
484 (75) 500 (75) 2025 (74)
0.09 1.74 0.09 1.74 0.08 1.74 0.09
11 84 12 92 14 82 14
3 28 3 30 4 27 4
553 (85) 556 (83) 2191 (80)
81 (13) 128 (19) 321 (12)
21 78 23 82 25 78 23
-3.4) 2.7 (2.1-3.4) 2.7 (2.2-3.4) 2.7 (2.1-3.4)
433 (67) 422 (63) 1692 (62)
467 (72) 475 (71) 1803 (66)
364 (56) 525 (78) 1267 (46)
-6.3) 5.9 (5.4-6.6) 6.2 (5.6-7.5) 5.8 (5.3-6.5)
4-1.90) 1.54 (1.16-2.13) 1.77 (1.31-2.55) 1.41 (1.04-2.00)
2-1.51) 1.19 (0.97-1.44) 1.13 (0.93-1.36) 1.21 (1.00-1.47)
9 97 9 105 10 95 12
21 145 22 145 21 142 22
11 84 12 83 11 83 11
173 (27) 160 (24) 774 (28)
413 (64) 451 (67) 1702 (62)
111 (17) 140 (21) 483 (18)
45 (7) 52 (8) 176 (7)
ipoprotein.
isease category.
ameter in 2726 patients with clinically evident
e 2 Quartile 3 Quartile 4
I)  (95% CI)  (95% CI)
; 1.09) 0.60 (0.02; 1.21) 1.39 (0.78; 2.00)
; 1.09) 0.57 (0.04; 1.18) 1.34 (0.73; 1.94)
; 1.06) 0.53 (0.09; 1.15) 1.33 (0.69; 1.97)
; 1.02) 0.62 (0.03; 1.21) 1.67 (1.06; 2.27)
; 0.91) 0.40 (0.20; 1.00) 1.43 (0.82; 2.04)
; 0.85) 0.31 (0.30; 0.92) 1.41 (0.77; 2.05)
height and ever smoking. Model III: Model II additionally adjusted for
od pressure.
he difference in infrarenal aortic diameter (mm) relative to the quartile with
n the highest quartile of intra-abdominal fat had 1.34 mm larger infrarenalically
uart
n 7
.3
59
(74)
74
79
26
(78)
(9)
77
(2.1
(60)
(64)
(35)
(5.3
(1.0
(1.0
92
40
82
(30)
(63)
(16)
(6)
nsity lic di
artil
95% C
0.11
0.10
0.14
0.17
0.27
0.35
d for
lic blo
cates t
withifewer components (adjusted , 1.74; 95% CI, 0.46-3.01).
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This study found that intra-abdominal fat accumula-
tion is associated with larger infrarenal aortic diameters in
patients with clinically evident arterial disease. Moreover,
among these high-risk patients, infrarenal aortic diameter
was slightly larger in patients with metabolic syndrome
compared with those without metabolic syndrome and
increased with an increment in the number of metabolic
syndrome components.
Our findings are in agreement with several studies that
found weight,15 waist circumference,15,16 and body mass
index,14,15 were associated with larger aortic diameters or
the presence of abdominal aortic aneurysm in the general
population. In contrast, a recent study did not find a
difference in bodymass index in middle-agedmen with and
without abdominal aortic aneurysm.18 Our study used
waist circumference and intra-abdominal fat (measured
using ultrasonography) as two various estimates of abdom-
inal obesity.32 We also measured waist circumference be-
cause of its usefulness in clinical practice. Previously, waist
circumference, a crude measure of abdominal visceral obe-
sity, was found to be associated with an increased cardio-
vascular risk.1 In the current study, intra-abdominal fat and
waist circumference were both associated with larger infra-
renal aortic diameters in patients with clinically evident
arterial disease.
Several factors may explain the increased diameters of
the infrarenal aortic artery among patients with more intra-
abdominal fat. Intra-abdominal fat is associated with the
development of interrelated metabolic abnormalities clus-
tering in the metabolic syndrome and are all involved in
accelerating atherosclerotic disease.4 The dilatation of the
abdominal aortic artery is a complex process in which
atherosclerosis plays a leading role.10 Indeed, we found that
patients with metabolic syndrome, the clustering of meta-
Table III. Metabolic syndrome and its components in rel
clinically evident arterial disease
Variable No.
Metabolic syndrome presentc 1267
Number of components
0 131
1 518
2 810
3 680
4 400
5 187
aModel I: age and sex adjusted. Model II: Model I, additional adjusted for
bRegression coefficients with 95% confidence interval (CI). For presence of
between patients with and without metabolic syndrome. For example, pa
compared with those without metabolic syndrome (model II). For compon
any component of metabolic syndrome; for example, patients with five com
compared with those without any component of metabolic syndrome (mod
cAccording to Adult Treatment Panel III.bolic abnormalities associated with obesity, had larger in-frarenal aortic diameters than those without. This was in
line with previous studies that found metabolic abnormal-
ities, such as elevated blood pressure, and dyslipidemia,
were associated with abdominal aortic diameter14,15 or
abdominal aortic aneurysm11-13,18 in the general popula-
tion. These studies, however, provided conflicting results,
particularly for elevated blood pressure.
Furthermore, the increased diameters of the infrarenal
aortic artery among patients with more intra-abdominal fat
could be due to the increased insulin resistance associated
with obesity. In an insulin-resistant state, abdominal fat
secretes in the systemic circulation large quantities of in-
flammatory cytokines, such as TNF- and IL-6, all of which
are involved in the process of atherosclerosis2 and thereby
contribute to aortic dilatation.10 In addition to accelerating
atherosclerosis, inflammatory processes likely mediate the
connective tissue destruction of the aortic wall.20 Adipocy-
tokines, such as TNF-, cause the release of proteases that
weaken the aortic matrix19 and inhibit the synthesis of
collagen.33
An accumulation of intra-abdominal fat may also di-
rectly affect the aortic wall from outside to inside by releas-
ing a large number of proinflammatory adipocytokines
(TNF-, IL-6) close to the aortic artery. Macrophages
attracted by abdominal fat–derived signals may subse-
quently traverse across the peritoneum to the aortic wall
and elicit a local inflammatory response. In addition, intra-
abdominal fat may generate cytokine signals to the aortic
wall through the periaortic fat. Human periaortic fat was
found to be a source of cytokines and chemokines22 with
potential chemotactic activity. Also, the amount of periaor-
tic fat markedly increased by a high-fat diet in rodents,
implying a role for periaortic fat in obesity-associated vas-
cular disease.22,34
In the current study, we found that an accumulation of
to infrarenal aortic diameter in 2726 patients with
Infrarenal aortic diameter (mm)
Model I a Model II
 (95% CI)b  (95% CI)
0.72 (0.29 to 1.15) 0.70 (0.27 to 1.13)
0 0
0.42 (0.68 to 1.52) 0.51 (0.58 to 1.60)
0.72 (0.34 to 1.79) 0.79 (0.26 to 1.85)
0.93 (0.15 to 2.01) 1.02 (0.05 to 2.09)
1.60 (0.47 to 2.73) 1.66 (0.53 to 2.78)
1.80 (0.51 to 3.08) 1.74 (0.46 to 3.01)
t, and ever smoking.
bolic syndrome,  indicates the difference in infrarenal aortic diameter (mm)
with metabolic syndrome had 0.70 mm larger infrarenal aortic diameters
f metabolic syndrome,  indicates the difference relative to patients without
nts of metabolic syndrome had 1.74 mm larger infrarenal aortic diametersation
heigh
meta
tients
ents o
pone
el II).intra-abdominal fat was associated with larger aortic diam-
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not determined in this study, our data suggest that intra-
abdominal fat may play a role in the process of aortic
dilatation. Thus, interventions aimed at lowering waist
circumference may help to modify the chronic inflamma-
tory state, insulin resistance, and associated hypertension
and dyslipidemia and therefore delay the enlargement of
the aortic diameter. A previous study found that an en-
larged diameter of the infrarenal aorta was associated with
an increased all-cause mortality, of which a major part was
caused by cardiovascular disease.7
Several studies indicate that patients with diabetes are
less likely to have an enlargement of the aortic diameter
than those without diabetes.28,35 These studies proposed
that glycemia-associated alterations in vascular matrix may
protect against dilatation of the aortic wall, because high
glucose accelerates synthesis of collagen36 and deposition
of advanced glycation end products may impair matrix
remodeling and proteolysis.37 In the present study, how-
ever, the relation of intra-abdominal fat with infrarenal
aortic diameter was not different in patients with and
without diabetes. Also, several studies reported an associa-
tion between abdominal aortic dilatation and peripheral
arterial occlusive disease,38 and abdominal obesity is highly
prevalent in patients with peripheral arterial disease.23 In
line with this, we found that the association between intra-
abdominal fat and infrarenal aortic diameter was stronger in
patients with a reduced ABPI.
We acknowledge study limitations. Owing to the cross-
sectional design, only assumptions about possible etiologic
relationships can be made. Furthermore, although CT has
been considered to be the most accurate and reproducible
technique formeasuring intra-abdominal fat,39 ultrasonog-
raphy has been proposed as a valid alternative tech-
nique.25,40 Also, different skeletal dimensions were not
measured in the screening program; therefore, we could
not additionally adjust the relationship between intra-
abdominal fat and infrarenal aortic diameter for the dimen-
sion of the individual’s skeleton. We used the Adult Treat-
ment Panel III definition of metabolic syndrome5 because
it is most commonly used in studies, is best related with the
development of vascular diseases, and is easy to use in
clinical practice; however, we realize that the metabolic
syndrome has other definitions.4
CONCLUSION
Intra-abdominal fat accumulation and metabolic syn-
drome are associated with larger infrarenal aortic diameters
in patients with clinically evident arterial disease. These data
may indicate a role for intra-abdominal fat in the develop-
ment of larger aortic diameters.
The help ofM. Edlinger for data coordination is greatly
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